文献速递神经MR

动态对比增强MR成像中预bolus T1测量与固定T1值在区分胶质母细胞瘤同步放化疗后真性进展与假性进展中的比较

Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Chemotherapy.
PubMed 文献 · AJNR Am J Neuroradiol · 2017-10-26

本回顾性研究纳入37例经组织病理学确诊的胶质母细胞瘤患者,在替莫唑胺放化疗后出现新增强病灶,分为真性进展15例和假性进展22例。比较使用固定T1值(1000 ms)与实测T1值计算的动态对比增强药代动力学参数在鉴别真性进展与假性进展中的诊断效能。结果显示固定T1值得到的速率转移常数是唯一独立预测因子,AUC为0.752,留一交叉验证敏感度和特异度分别为73.3%和59.1%。

要点

  • 固定T1值(1000 ms)计算的速率转移常数在真性进展组显著高于假性进展组(P=0.010)。
  • 多因素分析显示固定T1值的速率转移常数是唯一独立变量(OR=1.77×10^5)。
  • 固定T1值速率转移常数诊断真性进展的AUC为0.752,留一交叉验证敏感度73.3%、特异度59.1%。

核心结论

  • 固定T1值计算的动态对比增强参数速率转移常数可作为区分胶质母细胞瘤放化疗后真性进展与假性进展的较优标志物。

研究设计与样本

  • 回顾性研究,纳入37例经组织病理学确诊的胶质母细胞瘤患者,在替莫唑胺放化疗后出现新增强病灶,其中真性进展15例、假性进展22例;采用固定T1值1000 ms和多重翻转角法实测T1值分别计算动态对比增强药代动力学参数。

诊断标准与关键数值

  • 固定T1值的速率转移常数多因素分析OR为1.77×10^5,ROC分析AUC为0.752(P=0.002),留一交叉验证敏感度73.3%(11/15)、特异度59.1%(13/20)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Glioblastoma is the most common primary brain malignancy and differentiation of true progression from pseudoprogression is clinically important. Our purpose was to compare the diagnostic performance of dynamic contrast-enhanced pharmacokinetic parameters using the fixed T1 and measured T1 on differentiating true from pseudoprogression of glioblastoma after chemoradiation with temozolomide.

MATERIALS AND METHODS: This retrospective study included 37 patients with histopathologically confirmed glioblastoma with new enhancing lesions after temozolomide chemoradiation defined as true progression (n = 15) or pseudoprogression (n = 22). Dynamic contrast-enhanced pharmacokinetic parameters, including the volume transfer constant, the rate transfer constant, the blood plasma volume per unit volume, and the extravascular extracellular space per unit volume, were calculated by using both the fixed T1 of 1000 ms and measured T1 by using the multiple flip-angle method. Intra- and interobserver reproducibility was assessed by using the intraclass correlation coefficient. Dynamic contrast-enhanced pharmacokinetic parameters were compared between the 2 groups by using univariate and multivariate analysis. The diagnostic performance was evaluated by receiver operating characteristic analysis and leave-one-out cross validation.

RESULTS: The intraclass correlation coefficients of all the parameters from both T1 values were fair to excellent (0.689-0.999). The volume transfer constant and rate transfer constant from the fixed T1 were significantly higher in patients with true progression (P = .048 and .010, respectively). Multivariate analysis revealed that the rate transfer constant from the fixed T1 was the only independent variable (OR, 1.77 × 105) and showed substantial diagnostic power on receiver operating characteristic analysis (area under the curve, 0.752; P = .002). The sensitivity and specificity on leave-one-out cross validation were 73.3% (11/15) and 59.1% (13/20), respectively.

CONCLUSIONS: The dynamic contrast-enhanced parameter of rate transfer constant from the fixed T1 acted as a preferable marker to differentiate true progression from pseudoprogression.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Nam JG, Kang KM, Choi SH, et al. Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Chemotherapy. AJNR Am J Neuroradiol. 2017. PMID: 29074633. doi:10.3174/ajnr.A5417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。